- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
-
- Saigusa Daisuke
- Laboratory of Biomedical and Analytical Sciences, Faculty of Pharma-Science, Teikyo University Tohoku Medical Megabank Organization, Tohoku University
Search this article
Description
<p>The metabolome is a group of small molecules that reflect phenotypic changes; this set of molecules is a potential source of biomarkers to predict the risk of disease development and progression. Therefore, it is necessary to establish a comprehensive and precise method to analyze the metabolome in biological samples. Mass spectrometry (MS) is one of the most suitable technologies to detect those molecules for metabolic profiling. In particular, liquid chromatography (LC)-MS-based methodology has been applied to various disease models and clinical samples, and biomarker candidates have been identified in previous studies. However, it is necessary to clarify their functions by in vivo research, and their molecular mechanisms in cells and/or tissues should be considered before the markers are deemed clinically applicable. MS imaging (MSI) is a promising technology that can visualize molecules on tissue surfaces without labeling and thus can clarify the distribution of biomarker candidates on tissue to evaluate the results by means of LC-MS-based analysis. Here, we describe the outline of the protocols for biomarker discovery by LC-MS and explain the utilization of integrated analyses using LC-MS and MSI to evaluate the function of biomarker candidates.</p>
Journal
-
- Medical Mass Spectrometry
-
Medical Mass Spectrometry 7 (1), 2-16, 2023-06-25
Japanese Society for Biomedical Mass Spectrometry